PANDEMIC PROVIDER WEEKLY BROWN BAG

Updated December 2022
Updates
COVID-19 Vaccine Presentations Available to Order in ASIIS Job Aid

*NEW* Pfizer-BioNTech Bivalent (Ages 6 months - 4 years) - Maroon Cap

100-dose minimum order
- 10-dose multi-dose vial
- NDC 59267-0609-02

*NEW* Moderna Bivalent Booster (Ages 6 months - 5 years) - Dark Pink Cap with Yellow Border on label

100-dose minimum order
- 2-dose multi-dose vial
- NDC 80777-0283-99

*NEW* Spikevax is No Longer Available to Order in ASIIS
## ADHS Vaccine Reference Sheets - Pfizer-BioNTech

**NEW** Pediatric Pfizer **Monovalent & Bivalent** (Ages 6mo - 4 years) - Maroon Cap
- PEDIATRIC Pfizer Vaccine Reference Sheet

**Pfizer Bivalent Booster** (Ages 5-11) - Orange Cap
- Pfizer Vaccine Reference Sheet

**Pfizer** (Ages 5-11) - Orange Cap
- PEDIATRIC Pfizer Vaccine Reference Sheet

**Comirnaty/Pfizer** (Ages 12+) - Gray Cap
- Comirnaty/Pfizer Vaccine Reference Sheet

**Pfizer Bivalent Booster** (Ages 12+, No Diluent) - Gray Cap
- Pfizer Vaccine Reference Sheet
ADHS Vaccine Reference Sheets - Moderna

Moderna Bivalent Booster (Ages 6 months - 5 years) - Dark Pink Cap with Yellow Border on label
- Moderna Vaccine Reference Sheet

Pediatric Moderna Blue Cap with Magenta border on label (Ages 6mo - 5 years)
- Moderna Vaccine Reference Sheet

Pediatric Moderna Blue Cap with Purple Border on label (Ages 6 - 11 years)
- Moderna Vaccine Reference Sheet

Moderna Bivalent Booster (Ages 6+) - Blue Cap
- Moderna Vaccine Reference Sheet

Moderna (Ages 12+)
- Moderna Vaccine Reference Sheet
COVID-19 Vaccination Schedule for Primary and Booster Doses

COVID-19 Vaccination Schedule for people who are NOT and who ARE Moderately or Severely Immunocompromised

*For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

✝ A monovalent Novavax booster dose maybe used in limited situations in people 18 years and older who completed a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable or unwilling to receive an mRNA vaccine. The monovalent Novavax booster dose is administered at least 6 months after completion of a primary series.

‡Janssen COVID-19 dose should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a
COVID-19 Vaccine Program
ADHS COVID-19 Vaccine Website
azhealth.gov/covid19vaccine
ADHS Find Vaccine webpage [azhealth.gov/findvaccine]

- The locations of vaccination sites
- Filter to sort by vaccine type
- Use the patient portal at [podvaccine.azdhs.gov](podvaccine.azdhs.gov) to make an appointment for a relative
- Appointments recommended but no longer required at state-operated sites
Pandemic Provider Onboarding Start Form

- All facilities must onboard to be able to order/administer COVID-19 vaccines
- **Pandemic Vaccine Provider Onboarding Tool** - Job Aid (bottom right)
- Wait until you’re at the facility to onboard so you can upload photos of inside and outside of units
- Read through forms for important requirements
- Note: Per the CDC Agreement, COVID-19 vaccines must be recorded in the vaccine recipient’s record, the required information reported to the relevant state, local, or territorial public health authority, and decremented from the inventory within 24 hours of administration.
Required Reporting

- ASIIS
  - for inventory accounting and dose administration data within 24 hours
    - Required even if you use an EHR, ADHS VMS app, etc.
    - Verify ASIIS Lot Number > Reconciliation page (ASIIS Inventory) numbers should be matched between the quantity on hand and physical inventory columns
  - Vaccine Inventory Management course in AIPO Train
- Vaccines.gov/CDC VaccineFinder weekly inventory by Fridays
- County surveys as required by your local jurisdiction

Your ASIIS inventory is used by local, state, and federal leaders to make vaccine ordering decisions - It MUST be accurate
COVID-19 Inventory Management Reminders

In order to ensure that provider sites are being good stewards of the COVID-19 vaccines, the CDC has emphasized that each COVID-19 vaccination site should have at most 3-4 weeks of vaccine inventory on hand.

- Place smaller, more frequent orders to avoid stockpiling doses
- Use the data in ASIIS to determine how many doses you use & how many doses are on hand to place an order for an appropriate amount of doses
- Use the ADHS vaccine transfer matchmaker website to request a smaller quantity of doses then can be ordered in ASIIS
- Administered doses must be entered in ASIIS within 24 hours and decremented from the ASIIS inventory
- CDC VaccineFinder (vaccines.gov) inventory must be updated weekly by Friday
- Wasted/Expired Doses must be reported on signed and complete wasted/expired forms weekly
Off-Label Use

Pandemic providers should be aware that they must use COVID-19 vaccines according to FDA and CDC guidance. Use of COVID-19 vaccines outside of FDA and CDC recommendations (“off label”) is a violation of the provider agreement.

- Providers may not be covered under PREP Act and therefore not have the immunity from prosecution that the PREP Act provides.
- Recipients of an “off-label” COVID-19 vaccine dose may not be covered by the Countermeasure Injury Compensation Program if they were to have serious adverse events from the vaccine.
- Providers who violate the CDC agreement may not be able to remain as part of CDC programs.
- COVID-19 vaccine administration fees may not be covered if the dose were given “off-label.”
CDC Website: VFC vs. COVID-19 Vaccination Programs

- Separate programs with separate agreements
- Distinct requirements for each
- Help VFC providers understand difference between program requirements

**Vaccines for Children Program vs. CDC COVID-19 Vaccination Program**

As Emergency Use Authorization of COVID-19 vaccine products expand to include adolescents and children, it is critical to enroll providers in the COVID-19 Vaccination Program to ensure equitable access to COVID-19 vaccination services. Providers enrolled in the Vaccines for Children (VFC) program are well situated to serve in this capacity due to their direct access to the younger patient population and their familiarity with vaccine administration and federal vaccine programs. Though the VFC and COVID-19 Vaccination programs are both federal government programs, they work with distinct requirements based on the associated funding legislation. For this reason, the provider agreements remain separate, and VFC providers must sign and adhere to the requirements of the CDC COVID-19 Vaccination Program Provider Agreement in order to receive and administer COVID-19 vaccines. The table below has been developed to assist VFC providers in understanding the difference between the programs’ requirements. Program differences are in bold.

<table>
<thead>
<tr>
<th></th>
<th>VFC Program</th>
<th>COVID-19 Vaccination Program</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Provider Enrollment</strong></td>
<td>- Providers enroll via state/local immunization program enrollment system and procedures.</td>
<td>- Providers enroll via state/local immunization program enrollment system and procedures.</td>
</tr>
<tr>
<td></td>
<td>- Providers must complete and sign state/local immunization program Vaccines for Children Program Provider Agreement and VFC Program Provider Agreement Form.</td>
<td>- Providers complete and sign CDC COVID-19 Vaccination Program Provider Agreement, Sections A and B.</td>
</tr>
<tr>
<td><strong>Vaccine Ordering</strong></td>
<td>- Providers order routine childhood vaccines via state/local immunization program-designated ordering system and procedures.</td>
<td>- Providers order COVID-19 vaccines via state/local immunization program-designated ordering system and procedures.</td>
</tr>
<tr>
<td></td>
<td>- Providers must be fully trained in vaccine administration.</td>
<td>- Providers must be fully trained in vaccine administration.</td>
</tr>
</tbody>
</table>
Vaccines.gov/CDC VaccineFinder Provider Resources

The “organization email” listed in Section A of the CDC Agreement will get an email from vaccinefinder@auth.castlighthealth.com to sign up
● Weekly reporting by Friday of on-hand inventory quantities is a requirement
● Activating a location to display to the public is optional
● Providers can update display to the public function at any time
● Once COVID-19 vaccine locations are launched in Vaccines.gov, changes show publicly within 24 hours
● Check phone number in provider portal before making site public
● Vaccines.gov homepage - patients can find vaccines
● NOTE: If a site that is set to display to the public fails to update inventory within 72 hours, the availability information for each vaccine will display as “Call to confirm” on Vaccines.gov.

COVID-19 Administration Reporting Systems (CARS) Help Desk
● Monday through Friday, 8:00 am to 8:00 pm ET.
● CARS_HelpDesk@cdc.gov
● 1-833-748-1979
● Provide PIN when calling
Changes to the Required Temperature Incident Reporting Process for COVID-19 Vaccine Temperature Incidents

The Arizona Immunization Program Office (AIPO) is introducing changes to the required temperature incident reporting process for COVID-19 vaccine temperature incidents. This process is intended to improve incident turnaround times for providers by allowing them to take ownership of the process by following the steps in the Temperature Incident Instructions Checklist to obtain a viability determination from the manufacturer.

This is a required process for reporting all temperature incidents involving COVID-19 vaccines. The AIPO also encourages you to please fill out the survey at the end of the process as we value your feedback.
Daily COVID-19 Vaccine Tasks

Temperature Monitoring
- Twice per day monitor temperatures using the approved data logger
  - Document that you monitored temperatures using the paper temp log
    - Comirnaty/Pfizer ULT Celsius, Fahrenheit
    - Refrigerator Celsius, Fahrenheit
    - Moderna Freezer Celsius Fahrenheit
    - Document current, min, max, time, and initials
- If there are out of range temperatures, stop using the vaccines and submit an incident report to the AIPO
- Twice per month download and save the data logger data reports
  - Keep the data logger reports readily available for 6 years
  - Submit the data logger reports (in an acceptable file format: .xls, .txt, .ltd or .csv) to the AIPO upon request

Take a physical inventory count of doses in the cold storage units
- Compare the physical count to ASIIS lot number reconciliation inventory
- The inventories should be the exact same if doses given are entered properly in ASIIS. If you need to troubleshoot, use this job aid.
- Enter the weekly inventory by Fridays into CDC Vaccines.gov

Document doses administered in ASIIS within 24 hours
- Shipments must be marked “received” in ASIIS prior to administration in order for the doses to decrement from the inventory
If you would no longer like to participate as a pandemic provider please follow these steps

1. **Account for all doses in ASIIS**
   a. You are responsible for accounting for ALL of the doses shipped to you
   b. Ensure all doses shipped to the facility were received in ASIIS
   c. Ensure all doses administered were decremented from the ASIIS inventory
   d. ASIIS inventory reconciliation screen should be accurate

2. **If you still have doses**
   a. The doses will need to be transferred to another COVID-19 provider
   b. Transfers must have prior approval in ASIIS

3. Enter zero in CDC Vaccines.gov inventory when your inventory is depleted

4. Notify ADHS *after* doses have been accounted for
AIPO Train

- Training on ordering, receiving, and accounting for doses in ASIIS
- Information on data loggers - setting up, downloading data
- Onboarding resources
- Mass immunizations

How to Register
1. Go to https://aipo.myabsorb.com/?KeyName=PandemicProviders (This link automatically enters the enrollment key)
2. Enter required fields
3. Select Sign up
4. Click email activation link (important)

How to Log In
1. Go to https://aipo.myabsorb.com/#/login
2. Enter username and password (username will be email address)
3. Select Log In

For existing AIPO Train users: Enter enrollment key “PandemicProviders” to access pandemic-specific training

Questions? Email AIPOTrain@azdhs.gov
Administration Fee

- CMS has a toolkit to help health care providers prepare to administer vaccines
- Vaccine doses given to the American people at no cost
- Providers contractually agree to administer a COVID-19 vaccine regardless of an individual’s ability to pay and regardless of their coverage status
- May not seek any reimbursement, including through balance billing, from a vaccine recipient
- People without health insurance can get COVID-19 vaccine at no cost
- If you give COVID-19 vaccines to patients who are covered by AHCCCS you will need to be enrolled with AHCCCS in order to bill AHCCCS the administration fee
  - Register with AHCCCS here

Facilities cannot bill patients for the cost or admin fee for COVID-19 vaccines.
CVX Code and CPT Code Resources

- CMS - [Helpful for Billing](#)
- CDC - [Helpful for Uploading Data in EHR and ASIIS](#)
- ADHS - [Arizona HL7 Specific Rules](#)
TAPI - The Arizona Partnership for Immunizations (State immunization coalition)

- COVID-19 Resources
- COVID-19 Vaccine Billing Policy Information
- Resources for immunizations at off-site locations
CDC Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

CDC has issued revised Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations to assist with jurisdictional planning and implementation of satellite, temporary, or off-site vaccination clinics by public and private vaccination organizations.

The guidance is broken down into four categories:

- Planning activities
- Pre-clinic activities
- During the clinic activities
- Post-clinic activities

The guidance also provides information on additional considerations required during the COVID-19 pandemic, including physical distancing, personal protective equipment (PPE), and enhanced sanitation efforts.
Training for Healthcare Professionals

- CDC COVID-19 Vaccine Training Modules
- Public Health Foundation Training Plan
Immunization Action Coalition - immunize.org

- Info on administering vaccines
- Handouts for staff and patients
- “Ask the Experts” page
  - Includes COVID-19 vaccines
- Option to sign up for IAC Express email
  - Weekly email with updates to information and resources
CDC COVID-19 Vaccination Clinical Resources

COVID-19 Vaccination
Clinical Resources for Each COVID-19 Vaccine
Find information for COVID-19 vaccination administration, storage and handling, reporting, and patient education for each specific vaccine

Product Information by US Vaccine

ACIP Recommendations
Storage and Handling
General Vaccine Administration
Training and Education

V-safe
Clinical Considerations
Emergency Use Authorizations (EUAs)

Vaccination Provider Requirements & Support
Vaccination Data & Reporting Systems
Planning & Partnerships
Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States

Other resources:
- Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States
- COVID-19 Vaccine Administration Errors and Deviations
View or Print Toolkit

The Vaccine Storage and Handling Toolkit is a comprehensive guide that reflects best practices for vaccine storage and handling from Advisory Committee on Immunization Practices (ACIP) recommendations, product information from vaccine manufacturers, and scientific studies.

Vaccine Storage and Handling Resources

Access additional resources including web-based trainings, videos, checklists, and references related to vaccine storage and handling.

These example vaccine labels can be used to organize vaccines within the storage unit. Referenced in the storage and handling toolkit.

- [2020-2021 Influenza Season Vaccine Label Examples] [4 pages] (Sept 2020)
- [Vaccine Labels Examples] [20 pages] (Jan 2021)
Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites

- Emergency equipment that should be immediately available
- Routine observation periods following COVID-19 vaccination
- Early recognition of anaphylaxis
- Management of anaphylaxis at a COVID-19 vaccination location
- Considerations for anaphylaxis management in special populations
- Patient counseling
- Reporting anaphylaxis

Locations administering COVID-19 vaccines should adhere to CDC guidance, including screening recipients for contraindications and precautions, having necessary supplies and staff members available to manage anaphylaxis, implementing recommended post vaccination observation periods, and immediately treating suspected anaphylaxis with intramuscular epinephrine injection.
CDC v-safe system

- Give patients a **v-safe** information sheet at the time of vaccination
- Suggested healthcare provider script: *CDC has created a way for you to report how you feel after COVID-19 vaccination through a smartphone-based tool that uses text messaging and web surveys to check in with you. Here (or in your packet) is a **v-safe** information sheet with more details and simple instructions to sign up.*
- Parents and guardians can now enroll adolescents (ages 5 and older) in the v-safe after vaccination health checker℠ and complete health check-ins on their behalf after COVID-19 vaccination.
- Poster and website translated into multiple languages
VAERS Reporting and Safety Info - [vaers.hhs.gov](http://vaers.hhs.gov)

VAERS accepts all reports from everyone regardless of the plausibility of the vaccine causing the event or the clinical seriousness of the event.
EUA Fact Sheets

Routine vaccines are given with a Vaccine Information Statement (VIS)
COVID-19 vaccines under the Emergency Use Authorization (EUA) will be given with an EUA Factsheet.

- Pfizer Bivalent Booster Gray Cap (Ages 12+, No Diluent)
- Comirnaty/Pfizer Gray Cap (ages 12+) Fact Sheet
- Pfizer Orange Cap (ages 5-11yrs) EUA Fact Sheet
- Pediatric Pfizer Bivalent Booster Orange Cap (Ages 5 - 11yrs) EUA Fact Sheet
- Pfizer Maroon Cap Monovalent & Bivalent (ages 6mos-4yrs) EUA Fact Sheet
  - Pfizer EUA fact sheets translated in other languages
- Moderna Bivalent Booster Blue Cap (Ages 6+)
- Moderna Bivalent Booster Dark Pink Cap (Ages 6mos-5yrs) EUA Fact Sheet
- Moderna (ages 12+) EUA Fact Sheet
- Moderna (ages 6-11) EUA Fact Sheet
- Moderna (ages 6mos-5yrs) EUA Fact Sheet
  - Moderna EUA fact sheets translated in other languages
- Janssen Fact Sheet
  - Janssen EUA fact sheet translated in other languages
- Novavax Fact Sheet
  - Novavax EUA fact sheet translated in other languages
FDA gives Moderna COVID-19 vaccine full approval for use in ages 18 and older

- The Food and Drug Administration (FDA) has given full approval to the Moderna COVID-19 vaccine for use in those ages 18 and older. Ages 6mos to 17 are eligible for Moderna COVID-19 vaccines under FDA emergency use authorization.

- Moderna joins the Pfizer-BioNTech vaccine, which the FDA gave full approval to last August for use in ages 16 and older. Ages 6mos to 15 are eligible for Pfizer COVID-19 vaccines under FDA emergency use authorization.
Moderna Label Update

FDA recently approved updates to both label and the EUA fact sheet for the Moderna COVID-19 vaccine. Distribution of the Moderna vials with the updated labels (see new label above) began during the week of January 13, 2021.

What has changed on the label of the Moderna COVID-19 vaccine:

- The label has been updated to indicate a volume of 5.5mL.
- Doses for primary series and booster shots are now listed on the label.
- Important reminder not to exceed a maximum of 20 punctures per vial.

What remains the same for the Moderna COVID-19 vaccine:

- Formulation
- NDC
- Physical vial size
- Number of reportable doses
- Dose volumes (See Below)
- Reporting requirements
  - Wastage should continue to be reported based on 10 doses per vial.
- Proper dosage of Moderna COVID-19 Vaccine
  - Primary series doses 1 and 2 dosage = 0.5 mL
  - Additional primary dose (3rd) dosage for immunocompromised persons = 0.5 mL
  - Booster dosage = 0.25 mL
- Each vial can ONLY be punctured up to 20 times.
  - Once the vial has reached the 20-puncture limit, the vial should be discarded even if there is vaccine remaining in the vial.

For more information, please refer to the EUA fact sheet or Administration Overview for Moderna COVID-19 Vaccine | CDC.
Moderna Booster Reporting of Administered and Wasted Doses

- Quick rule of thumb: As long as the vial has been punctured 10 or 14 times and 10 or 14 doses were administered (regardless if they were full primary series doses or half booster doses) there will be no reported wastage.

- Example from the 14 dose vial table: 5 full doses (primary series) were administered and 5 half doses (booster doses) were administered before the 12 hour limit was reached. 4 doses should now be reported as wastage.
Moderna Puncture Tracking Log

- Keep track of how many times vials have been punctured
- Vials can only be punctured maximum of 20 times
- Mark half-doses vs full doses
- Can track 2 vials per log
Pediatric Pfizer **Orange Cap** (Ages 5-11) Job Aid

- **NEW** Can be stored in ULT freezers for up to 12 months
- Can be refrigerated for up to 10 weeks
- DO NOT use thermal shipping container or standard freezer for storage
- 10-dose vial
- Draw 0.2mL of diluted vaccine
- Discard 12 hours after dilution
Pediatric Pfizer Orange Cap (Ages 5-11) Manufacturing Date vs Expiration Date

- Date printed on vial and tray is **manufacturing date only**
- Base expiration date on storage method and manufacturing date. For example:
  - If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
  - If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.
- Use Pfizer Age 5-11 EUA Fact Sheet (Page 3)
- Use Pfizer website
Pediatric Pfizer Orange Cap (Ages 5-11) Shippers

- Shipper CANNOT be used for temp storage
- Can only be stored in ULT freezers and refrigerators
- Shipper does not need to be returned
- Controlant data logger **does** need to be returned

*Do NOT store contents in standard freezer*
You can only puncture the diluent once

Orders of Pfizer age 5-11 vaccine include ancillary kits that contain 10mL diluent vials. While these vials appear to contain sufficient diluent for multiple vials, they must only be used once.

- Diluent vials are a one-time-use item and should be discarded with the remaining content after each use.
- For each vial of vaccine, extract 1.3mL of diluent from a single-use vial to reconstitute 1.3mL of vaccine
- Do not be tempted to puncture diluent vials more than once.
Pfizer Gray Cap (Ages 12+) Job Aid

- *NEW* Can be stored in ULT freezers for up to 12 months
- Can be refrigerated for up to 10 weeks
- DO NOT use thermal shipping container or standard freezer for storage
- 6-dose vial
- **DO NOT** dilute prior to use
- DO NOT keep vaccine at room temperature for longer than 12 hours
- Discard vial 12 hours after first puncture
COVID-19 Vaccine Transfer Matchmaker Tool

- Share vaccine with other active COVID-19 providers
- Request vaccine from nearby locations if active providers need vaccine
- You can transfer needles as well
- Only serves as connection between providers
- All transfers must still have prior approval in ASIIS, must follow all transfer steps
- Matchmaker Tool Job Aid
  - Transfer steps
  - Helpful resources linked
ADHS Consent Form Template

- No Federal requirement for informed consent relating to immunization
- Available for providers who do not have own consent form
- Use with CDC Pre-Vaccination checklist
- Spanish ADHS consent form
- Spanish CDC Pre-Vaccination Checklist
ADHS Does Not Provide Exemption Forms for Adults for the COVID-19 Vaccine

- Individual facilities and employers may choose to set their own immunization requirements for adults
- If an employer is requiring a COVID-19 Vaccine for their employees, and the employee is refusing vaccination, direct that patient to their Human Resources department
- Adults who have questions on immunization exemptions, for any vaccine, should contact the facility or employer who has set the requirement
### Janssen COVID-19 Vaccine (Johnson & Johnson)

**Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose (Dosage/Route)</th>
<th>CDC</th>
<th>FDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen COVID-19 Vaccine (Johnson &amp; Johnson)</td>
<td>0.5 mL IM Injection</td>
<td>Inactive</td>
<td>FDA</td>
</tr>
</tbody>
</table>

#### Purpose
- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).

#### Policy
- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to vaccinate patients who meet all the criteria specified in the “Procedure” section below without the need for prior approval from the primary healthcare provider or direct order from the attending provider at the time of the interaction.

#### Procedure
- Assess persons 18 years of age and older for vaccination with Janssen COVID-19 Vaccine based on the following criteria:
- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Janssen COVID-19 Vaccine.
- If the recipient has received 1 dose of Janssen COVID-19 Vaccine, no additional primary series doses are needed. A booster dose is recommended 2 months to 8 weeks after the primary Janssen dose, any FDA-authorized or approved COVID-19 vaccine may be given.
- If 2 doses of an mRNA vaccine or a single dose of Janssen COVID-19 Vaccine has been administered, the person is considered fully vaccinated 2 weeks after completing the primary vaccination series.
- In situations where the first dose of an mRNA COVID-19 vaccine was received but the patient is unable to complete the series due to contraindications or adverse reactions, a booster dose of Janssen COVID-19 Vaccine, due to contraindications, may be given 2 months to 8 weeks after the previous dose of the Janssen COVID-19 Vaccine or at a minimum interval of 28 days after receipt of mRNA COVID-19 vaccine dose. However, contraindications should be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions. Consult referenced document for contraindications and precautions.

#### Vaccine Information
- **Thrombocytopenia syndrome (TTS) and thrombocytopenia:** Inform women aged 18-49 years of the increased risk of thrombocytopenia with thrombocytopenia products (TTP) in their age group after Janssen COVID-19 vaccination and about the availability of other authorized vaccines (e.g., mRNA vaccines).
- A second dose of Janssen COVID-19 Vaccine is not recommended for people who had TTS after their first dose. These people may receive a dose of mRNA COVID-19 vaccine at least 3 months (8 weeks) after their dose of Janssen vaccine and after their clinical criteria have stabilized.
- A consultation with the patient’s healthcare provider, including hematologists or other specialists, should be considered.

#### Additional Considerations
- Offer another FDA-authorized or approved vaccine (e.g., mRNA vaccine) to unvaccinated persons with a history of an episode of an acute, mediated syndrome characterized by thrombocytopenia and thrombocytopenia (e.g., heparin-induced thrombocytopenia) if they have had 2 doses of this vaccine or if they have had 1 dose and the vaccine is determined not to have been associated with the incident.

#### Notes
- Persons 18 years of age and older have a history of other thromboses not associated with thrombocytopenia can receive an FDA-authorized or approved vaccine.

- **With a history of fallopian-sterile syndrome (ERS):**
  - Cannot receive any FDA-authorized or approved COVID-19 vaccine. However, if the prescriber considers Janssen COVID-19 Vaccine a suitable vaccine, the prescriber should discuss with the patient the availability of mRNA COVID-19 vaccine that offers protection against COVID-19.

- **Persons who have received HCT or CAR T-cell therapy:**
  - Must consult with healthcare providers who were treated with Janssen COVID-19 vaccine prior to receiving HCT or CAR T-cell therapy with hematopoietic stem cell transplants at least 3 months (8 weeks) after completion of CAR T-cell therapy.

- **Booster doses:**
  - Administer a booster dose at least 3 months (8 weeks) after completion of the Janssen COVID-19 Vaccine primary dose.
## Standing Order Links - Novavax

### Link to Novavax

![Novavax COVID-19 Vaccine Information](image)

### Novavax COVID-19 Vaccine

**Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older**

<table>
<thead>
<tr>
<th>Vaccine Product</th>
<th>Dose/Injection Amount</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blue capped vial</td>
<td>5 μg/0.5 and 10 μg/1.0 μg of Matrix-M™ adjuvant</td>
<td>Intramuscular (IM) injection</td>
</tr>
</tbody>
</table>

**Purpose**
- To reduce morbidity and mortality from coronaviruses causing disease 2019 COVID-19 by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).  
- To protect individuals from COVID-19.

**Policy**
- Approved for use under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to vaccinate persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) for direct examination or direct order from the attending provider at the time of the transaction.

**Procedure**
- Access persons 18 years of age and older for the COVID-19 vaccine based on the following criteria:
  - Persons who are asymptomatic or severely immunocompromised:
    - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Novavax COVID-19 Vaccine.
    - If the recipient has received 1 previous dose of:
      - Novavax COVID-19 Vaccine, administer the second dose at least 2-6 weeks after the first dose.
      - A vaccine product that cannot be determined, no longer available, or not recommended, administer Novavax COVID-19 Vaccine at least 4 weeks after the first dose.
  - Persons with a history of myocarditis or pericarditis:
    - If history in prior COVID-19 vaccination, novavax Novavax COVID-19 Vaccine, after the episode of myocarditis or pericarditis has completely resolved.
    - If myocarditis or pericarditis occurred after the first dose of an mRNA or Novavax COVID-19 vaccine, generally experts advise waiting at least 2-6 weeks before receiving a dose of the second dose of an mRNA or Novavax COVID-19 vaccine. Vaccine can be considered for certain circumstances after the episode of myocarditis or pericarditis, has completely resolved. Consideration can be found at [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/unauthorized-use.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/unauthorized-use.html).

**Additional clinical considerations**
- Novavax COVID-19 Vaccine may be coadministered with other recently recommended vaccines without regards timing, including antimicrobial prophylaxis.
- For persons who received HCT or CAR-T cell therapy:
  - Those who received Novavax COVID-19 Vaccine prior to or during receiving HCT or CAR-T cell therapy with primary series of two doses (2 weeks) after transplant or CAR-T cell therapy.
- Screen for contraindications and precautions:
  - Contraindications:
    - History of:
      - Severe reaction to a previous dose of a component of the COVID-19 vaccine
      - Known reactive to a component of the vaccine
Novavax (Ages 12+)

- Novavax ADHS Reference Sheet
- Novavax COVID-19 Vaccine Overview and Safety | CDC
- Understanding Protein Subunit COVID-19 Vaccines

Novavax COVID-19 Vaccine
(Ages 12 years and older)

Refrigerator
- 2.0°C to 8.0°C
- Store unpunctured multi-dose vials of the Novavax COVID-19 vaccine in a standard refrigerator
- The vials should be stored in the original carton to protect from light
- The Novavax COVID-19 vaccine vial and carton do not have a printed expiration date
  - To find the expiration date access www.NovavaxCovidVaccine.com and enter the lot number on the United States Healthcare Professional Section of the website

Freezer (DO NOT USE FOR STORAGE)
- The Novavax COVID-19 Vaccine CANNOT be stored in the freezer

Vaccine
- Each multi-dose vial contains a maximum of 10 doses of 0.5 mL each
- Use 1 vial for every 10 recipients (10-dose vial)
- DO NOT dilute prior to use
- Gently swirl the vial, do NOT shake
- After the first needle puncture, store the vial at 2.0°C to 25.0°C for up to 6 hours
- Discard the vial if the vaccine is not used within 6 hours after the first puncture

Administration
- Draw 0.5mL of vaccine and inject intramuscularly (IM) in the deltoid muscle
- For people who are NOT moderately or severely immunocompromised a second dose is due 3-8 weeks after the first dose
- For people who ARE moderately or severely immunocompromised a second dose is due 21 days after the first dose

Disclaimer: Subject to change due to FDA EUA approval
UPDATED 08/24/2022
Janssen (Ages 18+)

- Janssen Vaccine Reference Sheet
- What Patients and Providers Need to Know About the Janssen Vaccine

**Vaccine Storage**

**Janssen COVID-19 Vaccine**

**Refrigerator**

- 2.0°C to 8.0°C
- 36.0°F to 46.0°F
- Store in refrigerator for up to 11 months
- DO NOT REFREEZE

**Dosage**

- Each vaccine vial contains 5, 0.5mL doses to be administered
- No reconstitution required
- Discard any punctured vial held at refrigerator temperatures after 6 hours
- Discard any punctured vial held at room temperature (maximally 25°C/77°F) after 2 hours

**Administration**

- Standard needles and syringes
- Draw 0.5mL and inject intramuscularly (IM)
- Single dose
- For adults 18 and older
- Not for children
- Can be administered until 11:59 p.m. EST on expiry date. Expiry dates can be verified on the Janssen website

The storage and handling information found on the Fact Sheet supersedes the storage and handling information on the carton and vial labels.

Disclaimer: Subject to change due to FDA EUA approval

Updated 4/12/22
Vaccine Manufacturer COVID-19 Websites

- Comirnaty/Pfizer COVID-19 Website
- Moderna COVID-19 Website
- Janssen COVID-19 Website
- Novavax COVID-19 Website

Modernova COVID-19 Vaccine

Global information about the Novavax COVID-19 Vaccine (recombinant, adjuvanted)

The approval status of the Novavax COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-Cov2373) varies worldwide. In countries where the vaccine has not been approved by the relevant regulatory authority or regulatory process, you will not find information about it on this site. This site will be updated as more information becomes available.

Download EUA Fact Sheet & Full Print for Vaccination Providers
Download EUA Fact Sheet for Vaccine Recipients & Caregivers
Look Up Vaccine Expiration Dates for Vaccination Providers
CDC COVID-19 Vaccine Resources

- CDC Pfizer (Comirnaty) Resource Page
- CDC Moderna Resource Page
- CDC Janssen Resource Page
- CDC Novavax Resource Page
## COVID-19 Vaccine Expiration Dates - Pfizer

<table>
<thead>
<tr>
<th>Vaccine Type</th>
<th>Cap Color</th>
<th>Age Group</th>
<th>Instructions</th>
</tr>
</thead>
</table>
| Pediatric Pfizer Maroon Cap Monovalent and Bivalent (Ages 6 months - 4 years) | Maroon | 6 months - 4 years | Date printed on vial and tray is manufacturing date only. Use the Pfizer website.

Base expiration date on storage method and manufacturing date. For example:
- If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
- If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.

| Pfizer Orange Cap (Ages 5-11) | Orange | 5-11 | Date printed on vial and tray is manufacturing date only. Use the Pfizer Age 5-11 EUA Fact Sheet (Page 3) Use the Pfizer website.

Base expiration date on storage method and manufacturing date. For example:
- If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
- If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.

| Pfizer Gray Cap (Ages 12+) | Gray | 12+ | Date printed on vial and tray is manufacturing date only. Use the Pfizer Gray Cap (Ages 12+) EUA Fact Sheet (Page 5) Use the Pfizer website.

Base expiration date on storage method and manufacturing date. For example:
- If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
- If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.

| Comirnaty Gray Cap (Ages 12+) | Gray | 12+ | Date printed on vial and tray is the expiration date. Use the Pfizer website to double check expiration dates.

| Pfizer-BioNTech Bivalent Booster (Ages 12+, No Diluent) - Gray Cap | Gray | 12+ | Date printed on vial and tray is the expiration date. Use the Pfizer website to double check expiration dates.

| Pediatric Pfizer-BioNTech Bivalent Booster (Ages 5 - 11 years) - Orange Cap | Orange | 5 - 11 | Date printed on vial and tray is the expiration date. Use the Pfizer website to double check expiration dates.

| Pfizer-BioNTech Bivalent Booster (Ages 12+, No Diluent) - Orange Cap | Orange | 12+ | Date printed on vial and tray is the expiration date. Use the Pfizer website to double check expiration dates.

| Pfizer-BioNTech Bivalent Booster (Ages 12+, No Diluent) - Orange Cap | Orange | 12+ | Date printed on vial and tray is the expiration date. Use the Pfizer website to double check expiration dates.
COVID-19 Vaccine Expiration Dates - Moderna, Novavax and Janssen

**Pediatric Moderna Blue Cap with Magenta Border on label** (Ages 6 months to 5 years)
- Use QR code
- Enter lot number on [expiration date checker website](#)

**Pediatric Moderna Blue Cap with Purple Border on label** (Ages 6 to 11 years)
- Use QR code
- Enter lot number on [expiration date checker website](#)

**Moderna Bivalent Booster Dark Pink Cap with Yellow Border on label** (Ages 6 months - 5 years)
- Use QR code
- Enter lot number on [expiration date checker website](#)

**Moderna Bivalent Booster Blue Cap** (Ages 6+)
- Use QR code
- Enter lot number on [expiration date checker website](#)

**Moderna Red Cap** (Ages 12+)
- Use QR code
- Enter lot number on [expiration date checker website](#)

**Novavax**
- Enter lot number on [expiration date checker website](#)

**Janssen**
- Use QR code
- Enter lot number on [expiration date checker website](#)
- Can be used until 11:59 EST on expiry date
CDC Expiration Date Tracking Tool

- Pfizer Gray Cap (ages 12+) , Orange Cap (ages 5-11yrs) & Maroon Cap (ages 6mo - 4yrs) doses can be refrigerated for up to 10 weeks
- Moderna doses can be refrigerated for up to 30 days
- Janssen doses can be refrigerated for up to 11 months
- Providers should check the latest expiry information on the manufacturer’s website before doses are removed from the unit
COVID-19 Vaccine and Beyond-use Dates (BUDs)

- CDC has developed tracking labels for refrigerators and freezers to help monitor and document cold storage dates.
- Assist with documenting transportation time and temperature.
- Available for both Moderna and Pfizer/Comirnaty vaccines.
  - Moderna COVID-19 Vaccine: Beyond Use Date/Time (BUD) Tracking Label for Vaccine During Refrigerator Storage (cdc.gov)
  - Pfizer-BioNTech COVID-19 Beyond Use Date/Time (BUD) Tracking Labels for Vaccine During Freezer or Refrigerator Storage (cdc.gov)
<table>
<thead>
<tr>
<th>Company</th>
<th>Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td>● Shippers <strong>DO NOT</strong> need to be returned</td>
</tr>
<tr>
<td></td>
<td>● Only controlant data logger needs to be returned</td>
</tr>
<tr>
<td>Moderna</td>
<td>● Return using the return label located on the inside of the box</td>
</tr>
<tr>
<td>Janssen (Ages 18+)</td>
<td>● Shippers do not need to be returned</td>
</tr>
<tr>
<td>Novavax (Ages 18+)</td>
<td>● Shippers do not need to be returned</td>
</tr>
</tbody>
</table>
Vaccine Process

Vaccines are widely available

- Providers enter their COVID-19 vaccine order in ASIIS
- AIPO will approve the order
- The order goes to CDC to Distributor/Manufacturer
- The order is shipped (will show in ASIIS)
- Provider receives shipment of ancillary kit and vaccine (may not be same day)
- Provider logs into ASIIS to mark doses as “received”
- Provider administers vaccine
- Provider reports the administered vaccine to ASIIS through their EHR, State VMS POD application, directly in ASIIS or using Mass Immunization Module in ASIIS
- The dose is subtracted from the ASIIS inventory if properly recorded in a patient’s ASIIS record
As of now, on March 22, 2022, the HRSA COVID-19 Uninsured Program will stop accepting claims for testing and treatment of COVID-19 due to lack of sufficient funds. On April 5, 2022, the program will also stop accepting vaccination claims due to a lack of sufficient funds. For additional information, please see the HRSA COVID-19 Uninsured Program Claims Submission Deadline FAQs and the White House Fact Sheet.

When is the final deadline to submit claims for reimbursement?

The deadlines to submit claims for each category of service are as follows:

- **Testing claims**: March 22, 2022, at 11:59 p.m. ET
- **Treatment claims**: March 22, 2022, at 11:59 p.m. ET
- **Vaccine administration claims**: April 5, 2022, at 11:59 p.m. ET

Any testing and treatment claims submitted in the Portal after March 22, 2022, will not be adjudicated for payment.

Any vaccine administration claims submitted in the Portal after April 5, 2022, will not be adjudicated for payment.
ASIIS Information
Placing Orders in ASIIS

- Providers who have an approved onboarding submission are able to order vaccines

- AIPO Train courses
  - How to Place an Order in ASIIS
  - Vaccine Inventory Management - information on ordering and inventory reconciliation
  - Sign up for Dose Accountability Webinar
    - Recordings available any time within AIPO Train course
  - Included in Pandemic Provider course bundle

- Use COVID-19 Vaccine Presentations Job Aid to help make ordering decisions
**Pfizer pediatric doses (5-11) should NOT be reported as adult doses**

**Reminder:**

The CPT and CVX codes for the Pfizer age 5-11 vaccine and the Pfizer age 12+ vaccine are different.

Please ensure that your EHR has been updated to document the vaccines correctly.

For information on Arizona HL7 Specific Rules for Version 2.5.1, click [here](#).

For information on List of Vaccine Names, Best ASIIS Selection and CPT/CVX Codes, click [here](#).

### List of Vaccine Names, Best ASIIS Selection and CPT/CVX Codes

<table>
<thead>
<tr>
<th>Vaccine trade name or common name</th>
<th>Fund</th>
<th>Best ASIIS Selection</th>
<th>Age (Ranges)</th>
<th>Dose</th>
<th>Route</th>
<th>Manufacturer/ NDC Number</th>
<th>CPT Code</th>
<th>CVX Code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COVID-19 Vaccines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COMIRNATY Pfizer COVID-19 Vaccine</td>
<td>PAN</td>
<td>COVID-19, mRNA-LNP, 95% effic; 3 ml, dose 14+ years 12+ years DLA 0.3 ml IM</td>
<td>Pfizer Inc. – FR NDC: 30037-2006-02 (Pack 10-dose w/127155 requ)</td>
<td>91000</td>
<td>200</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderna COVID-19 Vaccine</td>
<td>PAN</td>
<td>COVID-19, mRNA-LNP, 95% effic; 3 ml, dose 18+ years DLA 0.2 ml IM</td>
<td>Moderna – MDC NDC: 80777-6273-99 (Pack 10-dose w/127155 requ)</td>
<td>91007</td>
<td>207</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Arizona HL7 Specific Rules for Version 2.5.1*

The following specifications and rules supersede CDC and general HL7 guidelines when sending messages to the Arizona Immunization Program. Otherwise CDC and general HL7 guidelines apply.

- **MSH.1**: Field Separator will be the pipe | identified as (ASCII 24)
- **MSH.2**: Encoding Characters will be **^A** & **^B** identified as [ASCII 94, ASCII 126, ASCII 92, ASCII 38] respectively.
- **MSH.3**: Sending Application is required
- **MSH.4**: Sending Facility is required and shall be the IRMS ID assigned and provided by the ASIIS System.
- **MSH.5**: Receiving Application is required and shall always be ASIIS.
- **MSH.6**: Receiving Facility is required and shall always be ASIIS.
- **MSH.7**: Date/Time of Message is required and shall be in the following format (YYYYMMDDHHMMSS) and have a degree of precision to the minute generated.
- **MSH.9**: Message Type is required and shall be VXU|V04|VXXU_V04 for Unsolicited Vaccination Messages.
- **MSH.10**: Message Control ID is required and shall be unique for each message attempt from a sending facility with a maximum of 20 characters.
- **MSH.11**: Processing ID is required and because the ASIIS system has separate points for
Vaccine Transfer Process

- Both the sending and receiving providers will email data logger reports to ArizonaVFC@azdhs.gov
- Transfers must be approved in ASIIS prior to moving the doses
  - Enter the transfer in ASIIS prior to moving the doses
    - Information you will need for ASIIS
      1. The organization and facility sending the doses
      2. The organization and facility receiving the doses
      3. The quantity
      4. The lot number
  - When the doses arrive, mark them “received” in ASIIS. Do not administer doses before “receiving” them in the ASIIS inventory
- Only onboarded, active COVID-19 vaccine providers may receive COVID-19 vaccines
- Follow the USP transfer guidelines when packing the doses for transfer
  - Once frozen doses have been thawed they cannot go back into a freezer
- Wherever the vaccines are, data loggers must be with them to monitor the temperatures
- The ancillary kit must also be transferred with the doses
Vaccine Wastage

- **If vaccine expires before you can use it:**
  1. Follow the instructions on this [job aid](#) to process wastage in ASIIS. Please note that COVID vaccines will not need to be returned
  2. Dispose of the vaccine

- Expired/wasted COVID-19 doses should be disposed of in a sharps container or per the hazardous waste policy in your office

- Tear off the vial labels or mark the identifying information (lot number, NDC number, etc) with a black marker prior to disposing

- Expired/wasted COVID-19 vaccines **DO NOT** go back to McKesson or Pfizer at this time

- [How to Account for Wasted/Expired Doses Job Aid](#)
Correcting Negative Doses in ASIIS

Reconciling ASIIS inventory

- Giving more doses than what is in the ASIIS inventory will make the inventory negative, which will mean you cannot submit inventory reconciliation.
- Only if extracting extra doses from a vial
  - Ex. Extracting 15 doses from Moderna 14-dose vial
- AIPO Train module: Correcting Negative COVID-19 Doses in ASIIS
How to Run Reminder/Recall Report

- ASIIS Reminder/Recall Reports
- AIPO Train course
- Identify patients due/past due for vaccines
- Schedule patients
- Create letters, postcards, and mailing labels
If your ASIIS Inventory is not accurate

- Doses that have been administered to patients should not be removed from the Reconciliation page (Inventory) in ASIIS
- Troubleshoot why the doses did not decrement
  - Register for Dose Accountability Webinar in AIPO Train
  - Past Dose Accountability Webinar videos in course module
- Job aid to walk you through process of searching/adding/editing patient records manually in ASIIS
Mark doses as *Received* in VOMS 2.0 when the doses arrive

- Required regardless what system you use to document vaccine administration (EHR, VMS, ASIIS)

- When the doses arrive, mark them as *Received* in VOMS 2.0
  - Log into ASIIS
  - Go to Inventory Management> VOMS 2.0> Orders & Transfers > Click Receive button under Action header for the Inbound Order/Transfer
  - Verify the expiration date, lot number, and quantity of doses
  - Click the *Receive* button to receive the doses into the ASIIS Inventory

- After the doses are *Received* in VOMS 2.0, you may administer them

- If you administer doses before they are *Received* into the ASIIS inventory, they will not decrement from the ASIIS inventory
Funding Source - PAN

● The funding source should be PAN.

● If you have an EHR, your EHR vendor should send the code VXC50. On the user interface side, you will select PAN when administering.

● If you select VFC, State, Private, or something else as the funding source, the doses will not decrement from the ASIIS inventory.
Communication Resources
The AIPO sends granicus updates (email updates) on a variety of topics including COVID-19 vaccines, ASIIS, routine vaccines, etc. This library can be accessed at any time with the above link to view previously sent updates.
Ad Council COVID-19 Vaccination Campaign: It’s Up to You

getvaccineanswers.org

- Campaign site for consumers
- Answers common questions
- Provides vaccine information
- Link to Spanish site - www.DeTiDepende.org
- Creative materials that can be shared/used by providers
COVID-19 Vaccine Confidence Toolkit for Rural Jurisdictions

- Print ads
- Posters
- Brochure
- Social media posts
- Online resource guide
- PDFs can be customized using Adobe Acrobat Pro

Learn. Understand. Decide

COVID-19 vaccine communication toolkit

Customize the templates within the COVID-19 vaccine toolkit to easily develop internal and external communication materials!

With the support of the Delta Regional Authority (DRA) and the Health Resources Services Administration’s Federal Office of Rural Health Policy (FORHP), the Delta Region Community Health Systems Development (DRCCHS)
ADHS COVID-19 Communication Resources

- Posters in English and Spanish (sample [here](#))
- Addressing Misinformation ([here](#))
- Answering Patient Questions ([here](#))
- What to Expect After Getting COVID Vaccine ([here](#))
- What to Expect at Your Vaccine Appointment ([here](#))
- Vaccination Quick Answers ([here](#))
- Answering Common Patient Questions ([here](#))

COVID-19 Vaccine - Providers' Toolkit

- Order Form to request materials for your facility
HHS Video “Tell Me More About Vaccines”

The video answers commonly asked questions about the COVID-19 vaccine. The video shares why vaccines are so important and provides expert commentary and graphic illustration to help viewers understand the science of vaccine development. Tune in to hear from various experts, including Dr. Anthony Fauci (NIH), Dr. Stephen Hahn (FDA), and Dr. Robert Kadlec (ASPR), on the steps researchers and scientists are taking to develop a safe and effective vaccine. You are encouraged to add the video link to your website or promote it on social media.
FDA Emergency Use Authorization for Vaccines Explained

- What is an Emergency Use Authorization?
- Are the COVID-19 vaccines rigorously tested?
- What safety and effectiveness data are required to be submitted to FDA for an EUA request for a vaccine intended to prevent COVID-19?
CDC COVID-19 Vaccination Communication Toolkits

- For Medical Centers, Clinics, Pharmacies, and Clinicians
- For Healthcare Professionals and Pharmacists
- For LTCF Administrators and Leadership
- For Employers of Essential Workers
- For Staff of Organizations Serving Communities
- Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit

The toolkit contains a variety of resources that you can use virtually or in person (with proper COVID-19 safety precautions):

- Posters
- FAQ
- Key messages
- Slide decks

Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit

As parents' most trusted source of information on vaccines, pediatric healthcare professionals play a critical role in helping parents/guardians understand the importance of COVID-19 vaccination and assuring them that COVID-19 vaccines are safe and effective.

Your strong recommendation is critical for vaccine acceptance. Tell parents/guardians how important COVID-19 vaccines are to protecting their children's health.

Remind parents that after their family is fully vaccinated against COVID-19, they may start to do some things they had stopped doing because of the pandemic.

Even if you are not administering COVID-19 vaccines, you can help parents/guardians feel confident in choosing to get their children vaccinated against COVID-19 by addressing their questions and assuring them of the safety and effectiveness of COVID-19 vaccines.

The materials on this page will help you share clear and accurate information about COVID-19 vaccines when starting or continuing conversations with parents/guardians, as well as information for those who choose not to vaccinate their child.

COVID-19 Vaccination of Minors

Patients, parents, and guardians may have questions about consent for vaccination for minors recommended to receive a COVID-19 vaccine. Learn more at: Pfizer-BioNTech COVID-19 Vaccine.
Provider Resources for Patient Conversations About COVID-19 Vaccines

- How to talk to your patients about COVID-19 vaccination

**CDC's Key Points to Communicate to Your Patients:**
- COVID-19 vaccines are [safe and effective](#).
- Individuals 12 and up are all eligible to [get a COVID-19 vaccination](#).
- There are many locations to [find a COVID-19 vaccine](#).
- Having some [side effects](#) after vaccination is normal.
- You are not fully vaccinated until 2 weeks after the 2nd dose of a two-dose vaccine or 2 weeks after a one-dose vaccine.
CDC COVID-19 Vaccine Web Pages for the general public

- Benefits of Getting a COVID-19 Vaccine
- How COVID-19 Vaccines Work
- Frequently Asked Questions about COVID-19 Vaccination
- Understanding MRNA vaccines
- What to Expect at Your Appointment to Get Vaccinated for COVID-19
  - Translated in many languages
- When You’ve Been Fully Vaccinated
- Webpage COVID-19 Vaccines for Children and Teens
FAQs
FAQs

Q: If I am a VFC provider and already have an ASIIS PIN, do I still need to onboard?
●   A: Yes. If a facility location wants to administer COVID-19 vaccines, they will need to onboard and sign the CDC COVID-19 Agreement. The VFC Program and the COVID-19 vaccine program are separate programs with separate signed Agreements.

Q: How do I order COVID-19 vaccines in ASIIS?
●   A: Onboarded and active COVID-19 providers can follow the instructions in this job aid on how to place orders

Q: Where can I find these slides?
●   A: These slides can be found at azdhs.gov/covid19vaccine on the Provider Resources page. You can also find a link to the slides and the most recent recording in the Pandemic Provider Weekly Brown Bag course in AIPO Train.
THANK YOU!